Blaine Britt, MD
Internal Medicine · Brookhaven, MSNPI 1255593265
Payments from drug & device makers
Across 434 payments — averaging $15.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$1K
- Novo Nordisk$754
- Lilly USA, LLC$414
- Boehringer Ingelheim$285
- AbbVie$239
- plus $2K from 30 others
What the payments were for
- Food & beverage$6,617100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 105 | $1,769 |
| GSK | 81 | $1,158 |
| Novo Nordisk | 51 | $754 |
| Lilly USA, LLC | 26 | $414 |
| Boehringer Ingelheim | 24 | $285 |
| AbbVie(2 entities) | 16 | $239 |
| Bayer | 15 | $220 |
| Johnson & Johnson(2 entities) | 13 | $178 |
| Merck | 18 | $177 |
| Amgen | 10 | $165 |
| Viiv Healthcare Company | 7 | $155 |
| Supernus Pharmaceuticals, Inc. | 9 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $107 |
| Novartis | 7 | $106 |
| Mylan Specialty L.p. | 4 | $99 |
| Sanofi-aventis U.S. LLC | 6 | $77 |
| Shield Therapeutics Inc | 5 | $77 |
| Pfizer | 5 | $74 |
| Exact Sciences | 4 | $67 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $49 |
| Inspire Medical Systems, Inc. | 1 | $32 |
| Averitas Pharma Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $25 |
| Kyowa Kirin, Inc. | 1 | $24 |
| Shire North American Group Inc | 2 | $24 |
| Neurelis, Inc. | 1 | $21 |
| Hikma Pharmaceuticals USA | 1 | $20 |
| Lundbeck LLC | 1 | $17 |
| Dexcom, Inc. | 1 | $17 |
| Ardelyx, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Biohaven Pharmaceuticals, Inc. | 1 | $13 |
| Nestle Healthcare Nutrition Inc. | 1 | $13 |
| Ironshore Pharmaceuticals Inc. | 1 | $12 |
| Phathom Pharmaceuticals, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,617 in reported general payments places this provider in the 90th percentile of 846 internal medicine providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 241 | $247,019 |
| JardianceEmpagliflozin | 204 | $225,599 |
| TrulicityDulaglutide | 145 | $164,189 |
| LinzessLinaclotide | 163 | $147,805 |
| EliquisApixaban | 172 | $146,575 |
| JanuviaSitagliptin Phosphate | 132 | $134,406 |
| OzempicSemaglutide | 130 | $132,888 |
| MounjaroTirzepatide | 91 | $132,541 |
| XareltoRivaroxaban | 87 | $85,224 |
| Tresiba Flextouch U-200Insulin Degludec | 111 | $80,630 |
| EntrestoSacubitril/Valsartan | 41 | $52,876 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $48,538 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 65 | $43,740 |
| TradjentaLinagliptin | 30 | $32,125 |
| JanumetSitagliptin Phos/Metformin Hcl | 25 | $24,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,769 | $298,821338 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $414 | $296,730236 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $285 | $266,458251 claims |
| MerckJanuvia, Janumet, Belsomra | $177 | $172,436189 claims |
| AbbVieLinzess | $239 | $147,805163 claims |
| PfizerEliquis | $74 | $146,575172 claims |
| Novo NordiskOzempic | $754 | $132,888130 claims |
| Johnson & JohnsonXarelto | $178 | $85,22487 claims |
| GSKTrelegy Ellipta, Incruse Ellipta | $1,158 | $55,58597 claims |
| NovartisEntresto | $106 | $52,87641 claims |
| Hikma Pharmaceuticals USAMitigare | $20 | $9,75016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 846 internal medicine providers in Mississippi.
Other internal medicine in Brookhaven
- James HallBrookhaven$4.8M
- Ramiro MontalvoBrookhaven$10K
- Bob HutchinsJackson$4.6M
- Sidney GortonBelzoni$571K
- David PendleyGulfport$336K
- Sarah KerutJackson$319K
- Gabriel HernandezJackson$196K
- Kelly WilkinsonJackson$183K
- Magdy Gorgi-MikhailBiloxi$157K
- Christina BarlowJackson$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.